Developing a new adjuvant to enhance vaccine effectiveness against bacterial and fungal infections
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
This study is testing a new helper ingredient for vaccines called UM-1098, which aims to boost the immune response against tough infections like tuberculosis and certain bacteria, so that people can have better protection from serious illnesses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-10935819 on NIH RePORTER |
What this research studies
This research focuses on creating a novel synthetic adjuvant, UM-1098, designed to enhance the immune response against various bacterial and fungal pathogens, including tuberculosis and Pseudomonas aeruginosa. The approach involves using a specific receptor ligand and a nanoparticle delivery system that has shown safety and efficacy in animal models. By advancing this adjuvant towards human clinical trials, the research aims to improve vaccination strategies that have been limited by the lack of effective adjuvants for inducing Th17 immunity. Patients may benefit from more effective vaccines that provide better protection against serious infections.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals at high risk for infections caused by the targeted pathogens, such as those with compromised immune systems or chronic respiratory conditions.
Not a fit: Patients who are not at risk for the targeted infections or those who have already been vaccinated with effective vaccines may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly improve protection against serious bacterial and fungal infections.
How similar studies have performed: Previous research has shown success with similar approaches in developing adjuvants that enhance immune responses, indicating a promising potential for this novel adjuvant.
Where this research is happening
Missoula, United States
- University of Montana — Missoula, United States (Active)
Researchers
- Principal investigator: Evans, Jay — University of Montana
- Study coordinator: Evans, Jay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.